Gossamer Bio Inc (GOSS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Gossamer Bio Inc (GOSS) has a cash flow conversion efficiency ratio of 0.439x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-36.17 Million) by net assets ($-82.33 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Gossamer Bio Inc market capitalisation for the company's overall valuation and market capitalisation.
Gossamer Bio Inc - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Gossamer Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Gossamer Bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Gossamer Bio Inc ranked by their cash flow conversion efficiency. Explore how high is Gossamer Bio Inc's earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Icares Medicus Inc
TWO:6612
|
-0.003x |
|
Ilsung Pharm
KO:003120
|
0.000x |
|
Equillium Inc
NASDAQ:EQ
|
-0.273x |
|
Data International Co Ltd
TWO:5432
|
0.095x |
|
Star Holdings
NASDAQ:STHO
|
-0.030x |
|
MegaStudy Co. Ltd
KQ:072870
|
0.041x |
|
Bogota Financial Corp
NASDAQ:BSBK
|
0.002x |
|
Sedana Medical AB
ST:SEDANA
|
-0.009x |
Annual Cash Flow Conversion Efficiency for Gossamer Bio Inc (2016–2024)
The table below shows the annual cash flow conversion efficiency of Gossamer Bio Inc from 2016 to 2024. View Gossamer Bio Inc share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $29.49 Million | $-3.47 Million | -0.118x | +95.36% |
| 2023-12-31 | $62.77 Million | $-159.16 Million | -2.536x | +83.63% |
| 2022-12-31 | $12.08 Million | $-187.03 Million | -15.487x | -895.85% |
| 2021-12-31 | $121.46 Million | $-188.89 Million | -1.555x | -182.78% |
| 2020-12-31 | $320.68 Million | $-176.36 Million | -0.550x | -33.84% |
| 2019-12-31 | $352.49 Million | $-144.83 Million | -0.411x | -196.65% |
| 2018-12-31 | $-120.07 Million | $-51.04 Million | 0.425x | -49.22% |
| 2017-12-31 | $-6.86 Million | $-5.75 Million | 0.837x | +614.89% |
| 2016-12-31 | $-123.00K | $20.00K | -0.163x | -- |
About Gossamer Bio Inc
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical tr… Read more